Focal Segmental Glomerulosclerosis Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Dimerix Bioscience, Travere Therapeutics, Horizon Therapeutics, Pfizer, Goldfinch Bio, Certa Therapeutics, ZyVersa Therapeutics, Vertex Pharmaceuti

Focal Segmental Glomerulosclerosis Pipeline constitutes 15+ key companies continuously working towards developing 18+ Focal Segmental Glomerulosclerosis treatment therapies, analyzes DelveInsight.

Focal Segmental Glomerulosclerosis Overview:

Focal Segmental Glomerulosclerosis (FSGS) is a leading cause of idiopathic steroid-resistant nephrotic syndrome (SRNS) and can progress to end-stage kidney disease (ESKD). Its development involves a complex interaction among various cell types, including podocytes, endothelial cells, and the glomerular basement membrane. Podocytes, which are highly specialized and non-regenerative cells, play a crucial role in maintaining the structural integrity of the glomerulus and ensuring the proper functioning of the glomerular filtration barrier to prevent significant protein loss in the urine. Damage to or loss of podocytes triggers compensatory hypertrophy in the remaining podocytes to cover the capillary surface, leading to foot process effacement and proteinuria.

As the disease advances, there is also proliferation of mesangial, endothelial, and epithelial cells, followed by the collapse or contraction of glomerular capillaries, ultimately resulting in glomerulosclerosis (scarring of the glomeruli). Podocyte injury may be driven by viral or toxic exposures or by changes in intrarenal blood flow, such as increased glomerular pressure and hyperperfusion. Several morphological variants of FSGS have been identified, including the collapsing type (associated with mesangial hypercellularity), the cellular variant (characterized by endocapillary and extracapillary hypercellularity), and the tip lesion variant.

Download our report @ https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Focal Segmental Glomerulosclerosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Focal Segmental Glomerulosclerosis Therapeutics Market.

Key Takeaways from the Focal Segmental Glomerulosclerosis Pipeline Report

DelveInsight's Focal Segmental Glomerulosclerosis pipeline report depicts a robust space with 15+ active players working to develop 18+ pipeline therapies for Focal Segmental Glomerulosclerosis treatment.
​In March 2025, Travere Therapeutics submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking priority review for FILSPARI® (sparsentan) as a treatment for focal segmental glomerulosclerosis (FSGS). If approved, FILSPARI would become the first FDA-approved therapy for this rare kidney disorder. ​
The sNDA submission is supported by data from the Phase 3 DUPLEX Study and the Phase 2 DUET Study, which are among the largest interventional studies conducted in FSGS patients. Notably, the DUPLEX Study did not meet its primary efficacy endpoint over 108 weeks but demonstrated significant proteinuria reduction and higher remission rates compared to the active control. ​
Travere's decision to pursue FDA approval despite the DUPLEX Study's primary endpoint results is based on the observed reduction in proteinuria, which is considered a meaningful indicator of treatment benefit in FSGS. The FDA has shown openness to considering proteinuria reduction as a surrogate endpoint for approval in FSGS treatments. ​
Key Focal Segmental Glomerulosclerosis companies such as Dimerix Bioscience, Travere Therapeutics, Horizon Therapeutics, Pfizer, Goldfinch Bio, Certa Therapeutics, ZyVersa Therapeutics, Vertex Pharmaceuticals, Chinook Therapeutics, Delta 4, and others are evaluating new drugs for Focal Segmental Glomerulosclerosis to improve the treatment landscape.
Promising Focal Segmental Glomerulosclerosis pipeline therapies in various stages of development include DMX-200, Sparsentan, Dazodalibep and others.

Focal Segmental Glomerulosclerosis Pipeline Analysis
The Focal Segmental Glomerulosclerosis pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Focal Segmental Glomerulosclerosis Market.

Categorizes Focal Segmental Glomerulosclerosis therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Focal Segmental Glomerulosclerosis drugs under development based on:

Stage of development

Focal Segmental Glomerulosclerosis Route of administration

Target receptor

Monotherapy vs. combination therapy

Focal Segmental Glomerulosclerosis Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Focal Segmental Glomerulosclerosis Licensing agreements

Funding and investment activities supporting future Focal Segmental Glomerulosclerosis market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Focal Segmental Glomerulosclerosis Emerging Drugs
DMX-200: Dimerix Bioscience
Sparsentan: Travere Therapeutics
Dazodalibep: Horizon Therapeutics

Focal Segmental Glomerulosclerosis Companies

Around 15 or more prominent companies are actively working on developing therapies for Focal Segmental Glomerulosclerosis (FSGS). Among these, Dimerix Bioscience stands out with a drug candidate that has reached the most advanced stage of development-Phase III clinical trials.

DelveInsight's report covers around 18+ products under different phases of Focal Segmental Glomerulosclerosis clinical trials like

Focal Segmental Glomerulosclerosis Late stage Therapies (Phase III)
Focal Segmental Glomerulosclerosis Mid-stage Therapies (Phase II)
Focal Segmental Glomerulosclerosis Early-stage Therapies (Phase I)
Focal Segmental Glomerulosclerosis Pre-clinical and Focal Segmental Glomerulosclerosis Discovery stage Therapies
Focal Segmental Glomerulosclerosis Discontinued & Inactive Therapies

Focal Segmental Glomerulosclerosis pipeline report provides the Focal Segmental Glomerulosclerosis therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Focal Segmental Glomerulosclerosis Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Focal Segmental Glomerulosclerosis Therapies and Key Focal Segmental Glomerulosclerosis Companies: Focal Segmental Glomerulosclerosis Clinical Trials and recent advancements https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Focal Segmental Glomerulosclerosis Pipeline Therapeutic Assessment
• Focal Segmental Glomerulosclerosis Assessment by Product Type
• Focal Segmental Glomerulosclerosis By Stage
• Focal Segmental Glomerulosclerosis Assessment by Route of Administration
• Focal Segmental Glomerulosclerosis Assessment by Molecule Type

Download Focal Segmental Glomerulosclerosis Sample report to know in detail about the Focal Segmental Glomerulosclerosis treatment market @ Focal Segmental Glomerulosclerosis Therapeutic Assessment https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Focal Segmental Glomerulosclerosis Current Treatment Patterns
4. Focal Segmental Glomerulosclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Focal Segmental Glomerulosclerosis Late-Stage Products (Phase-III)
7. Focal Segmental Glomerulosclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Focal Segmental Glomerulosclerosis Discontinued Products
13. Focal Segmental Glomerulosclerosis Product Profiles
14. Focal Segmental Glomerulosclerosis Key Companies
15. Focal Segmental Glomerulosclerosis Key Products
16. Dormant and Discontinued Products
17. Focal Segmental Glomerulosclerosis Unmet Needs
18. Focal Segmental Glomerulosclerosis Future Perspectives
19. Focal Segmental Glomerulosclerosis Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Focal Segmental Glomerulosclerosis Pipeline Reports Offerings: https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.